Zacks Investment Research cut shares of SenesTech (NASDAQ:SNES) from a hold rating to a sell rating in a report issued on Thursday morning.

According to Zacks, “SenesTech, Inc. developed technology for managing animal pest populations through fertility control as opposed to a lethal approach. The Company’s fertility control product candidate, ContraPest(R), will be marketed for use initially in controlling rat infestations. SenesTech, Inc. is based in Flagstaff, Arizona. “

Separately, ValuEngine upgraded SenesTech from a hold rating to a buy rating in a report on Saturday, June 2nd.

Shares of NASDAQ SNES traded down $0.03 during trading on Thursday, hitting $0.86. 16,579 shares of the company were exchanged, compared to its average volume of 717,841. SenesTech has a 12-month low of $0.30 and a 12-month high of $3.87. The company has a quick ratio of 4.07, a current ratio of 5.05 and a debt-to-equity ratio of 0.05. The firm has a market cap of $20.61 million, a PE ratio of -0.77 and a beta of 2.56.

SenesTech (NASDAQ:SNES) last posted its quarterly earnings results on Monday, August 13th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.12). SenesTech had a negative return on equity of 214.75% and a negative net margin of 13,362.22%. The company had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.40 million. research analysts expect that SenesTech will post -0.61 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of Montreal Can purchased a new position in shares of SenesTech during the 2nd quarter worth $131,000. CVI Holdings LLC purchased a new position in shares of SenesTech during the 1st quarter worth $262,000. Finally, Sabby Management LLC raised its holdings in shares of SenesTech by 81.9% during the 1st quarter. Sabby Management LLC now owns 794,740 shares of the company’s stock worth $405,000 after acquiring an additional 357,877 shares during the period. Institutional investors and hedge funds own 8.11% of the company’s stock.

About SenesTech

SenesTech, Inc develops a technology for managing animal pest populations through fertility control. The company focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It is also developing a pipeline of fertility control and animal health products, including feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment.

Read More: Market Capitalization and Individual Investors

Get a free copy of the Zacks research report on SenesTech (SNES)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with's FREE daily email newsletter.